Associations between systemic-immune inflammation index and diabetes mellitus secondary to pancreatic ductal adenocarcinoma

Published: 7 December 2022| Version 1 | DOI: 10.17632/7tbz649pzf.1
guanhua chen


Diabetes mellitus (DM) occur very frequently in patients with pancreatic ductal adenocarcinoma (PDAC). Many studies support the concept that pancreatic cancer associated diabetes is a paraneoplastic phenomenon and chronic inflammation has been implicated as a potential contributor to the development of diabetes mellitus and its complications. A systemic immune-inflammation index (SII) has been considered as a good, stable index that reflects both local immune responses and systemic inflammation. It integrates three types of inflammatory cells, including platelet, neutrophil, and lymphocyte, and has been proposed as an indicator for systemic inflammation, a risk factor of major cardiovascular events, and a predictor of cancer outcomes We conducted a cross-section study to clarify whether SII level is associated with diabetes secondary to exocrine pancreatic disorders.



Diabetes, Pancreatic Ductal Adenocarcinoma